<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2360">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130437</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-3927-P101-EXT</org_study_id>
    <nct_id>NCT05130437</nct_id>
  </id_info>
  <brief_title>A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927</brief_title>
  <official_title>A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered&#xD;
      to participants with propionic acidemia (PA) who have previously participated in Study&#xD;
      mRNA-3927-P101 (NCT04159103).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess long-term safety and clinical activity of mRNA-3927. Participants with&#xD;
      PA who were previously enrolled and completed the end-of-treatment (EOT) Visit of the&#xD;
      mRNA-3927-P101 study will have the option to enroll into this extension study provided all&#xD;
      eligibility criteria have been met.&#xD;
&#xD;
      The study will include 2 periods: 1) Treatment Period and 2) Follow-up Period (up to 2 years&#xD;
      after the last dose of study drug). All participants will enter the study receiving mRNA-3927&#xD;
      at the same dose and at the same dosing interval last received in the mRNA-3927-P101 study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2021</start_date>
  <completion_date type="Anticipated">December 4, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2029</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to End of Study Visit (up to 8 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma 2-Methylcitrate (2-MC) Levels</measure>
    <time_frame>Baseline, End of Study (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma 3-Hydroxypropionic Acid (3-HP) Levels</measure>
    <time_frame>Baseline, End of Study (up to 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK): Propionyl-CoA Carboxylase (PCC) Subunit α (PCCA) and Propionyl-CoA Carboxylase Subunit β (PCCB) mRNA (Serum) and SM-86 (Plasma) Levels</measure>
    <time_frame>Predose and End of Infusion up to 8 years postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinically Significant Events</measure>
    <time_frame>Baseline up to 8 years</time_frame>
    <description>Clinically significant events include hospitalization, emergency room visits, emergency interventions outside of healthcare settings, and complications of cardiomyopathy treated outside of hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metabolic Decompensation Events (MDEs)</measure>
    <time_frame>Baseline up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Healthcare Resource Utilization Visits</measure>
    <time_frame>Baseline up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Participants Missed School and Workdays</measure>
    <time_frame>Baseline up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-Polyethylene Glycol Antibodies</measure>
    <time_frame>Month 6 up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-PCC Antibodies</measure>
    <time_frame>Month 6 up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pediatric Quality-of-Life Inventory (PedsQL)</measure>
    <time_frame>Baseline, End of Study (up to 8 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Propionic Acidemia</condition>
  <arm_group>
    <arm_group_label>mRNA-3927</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-3927</intervention_name>
    <description>mRNA-3927 dispersion for IV infusion</description>
    <arm_group_label>mRNA-3927</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participated in Study mRNA-3927-P101.&#xD;
&#xD;
          -  Completed the EOT Visit in Study mRNA-3927-P101 within 10 days of first dose of&#xD;
             mRNA-3927 in current study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not expected to receive clinical benefit from continued mRNA-3927 administration, in&#xD;
             the opinion of the Investigator.&#xD;
&#xD;
          -  Any clinical or laboratory abnormality or medical condition that, at the discretion of&#xD;
             the Investigator, may put the individual at increased risk by participating in this&#xD;
             study.&#xD;
&#xD;
          -  History of liver and/or kidney transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-3927</keyword>
  <keyword>Propionic Aciduria</keyword>
  <keyword>Metabolism, Inborn Errors</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Inborn Amino Acid Metabolism, Inborn Errors</keyword>
  <keyword>Acidosis</keyword>
  <keyword>Acid-Base Imbalance</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Organic Acidemias</keyword>
  <keyword>Moderna</keyword>
  <keyword>mRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propionic Acidemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

